Cairo Pharmaceuticals results, Q2 2026
Net profit, assets, equity and cash flow for Q2 2026, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit125 millionEGP · −26.9% vs the same period a year earlier
Shareholders' equity1.02 billionEGP · +19.7% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Q2 2026 was about 125 million EGP, down −26.9% from 171 million EGP in Q2 2025.
Key lines against the same period a year earlier
This periodQ2 2025Change
Net profit125 million171 million−26.9%
Gross profit216 million293 million−26.2%
Total assets—1.74 billion—
Total liabilities—886 million—
Shareholders' equity1.02 billion850 million+19.7%
Total liabilities and equity2.15 billion1.74 billion+24.0%
Operating cash flow—80.71 million—
Investing cash flow—-34.29 million—
Financing cash flow-179 million-116 million−55.2%
Net change in cash—-69.23 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy